Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0140)
Name
Lycorine
Synonyms
lycorine; 476-28-8; Amarylline; Galanthidine; Narcissine; Licorine; Lycorine hydrochloride; (-)-Lycorine; NSC401360; NSC683873; CHEBI:6601; CHEMBL400092; I9Q105R5BU; GNF-PF-4974; Lycoran-1-alpha,2-beta-diol, 3,3-alpha-didehydro-; NSC-401360; NSC-683873; 9,10-(methylenedioxy)-3,12-didehydrogalanthan-1alpha,2beta-diol; NSC 401360; Galanthan-1,2-diol, 3,12-didehydro-9,10-(methylenebis(oxy))-, (1-alpha,2-beta)-; (1S,2S,3a1S,12bS)-2,3a1,4,5,7,12b-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol; (1S,2S,12bS,12cS)-2,4,5,7,12b,12c-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol; EINECS 207-503-6; UNII-I9Q105R5BU; 3,3a-Didehydrolycoran-1alpha,2beta-diol; Likorin; (1S,2S,12BS,12CS)-2,4,5,7,12B,12C-HEXAHYDRO-1H-(1,3)DIOXOLO(4,5-J)PYRROLO(3,2,1-DE)PHENANTHRIDINE-1,2-DIOL; 3,2.beta.-diol; Lycoran-1.alpha.,2.beta.-diol, 3,3a-didehydro-; LYCORINE [MI]; Lycoran-1alpha,2beta-diol, 3,3a-didehydro-; BSPBio_001302; KBioGR_000022; KBioSS_000022; SCHEMBL626071; BCBcMAP01_000100; KBio2_000022; KBio2_002590; KBio2_005158; KBio3_000043; KBio3_000044; DTXSID60197208; Bio2_000022; Bio2_000502; HMS1361B04; HMS1791B04; HMS1989B04; HMS3402B04; HMS3885I12; HY-N0288; BDBM50221066; MFCD00221746; NSC781764; s3903; Lycoran-1.alpha., 3,3a-didehydro-; AKOS000278045; CCG-208232; NSC-781764; IDI1_033772; QTL1_000052; SMP1_000184; NCGC00163413-01; NCGC00163413-02; NCGC00163413-03; NCGC00163413-07; MS-24104; NCI60_003767; CS-0008781; C08532; Q420314; BRD-K64909280-001-02-7; 3,12-[methylenebis(oxy)]-galanthan-1.alpha.,2.beta.-diol; Galanthan-1, 3,12-didehydro-9,10-[methylenebis(oxy)]-, (1.alpha.,2.beta.)-; Galanthan-1, 3,4-didehydro-11,12-[methylenebis(oxy)]-, (1.alpha.,2.beta.)-; (1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.0?,??.0?,?.0??,??]nonadeca-2,4(8),9,15-tetraene-17,18-diol; (1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol; 1H-[1,3]Dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol, 2,4,5,7,12b,12c-hexahydro-, (1S,2S,12bS,12cS)-; 2,4,5,7,12b,12c-Hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol, (1S,2S,12bS, 12cS)-; 2,5,7,12b,12c-Hexahydro-1H-[1,3]-dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol; 3KD

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C16H17NO4
IUPAC Name
(1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol
Canonical SMILES
C1CN2CC3=CC4=C(C=C3C5C2C1=CC(C5O)O)OCO4
InChI
InChI=1S/C16H17NO4/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19/h3-5,11,14-16,18-19H,1-2,6-7H2/t11-,14-,15+,16+/m0/s1
InChIKey
XGVJWXAYKUHDOO-DANNLKNASA-N
PubChem CID
72378
TTD Drug ID
D0MI0Q
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Hereditary Leiomyomatosis ICD-11: 2C90
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model 786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
A-498 cells Renal cell carcinoma Homo sapiens CVCL_1056
Caki-1 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0234
HK-2 cells Normal Homo sapiens CVCL_0302
Response regulation Lycorine could inhibit the proliferation in human renal cell carcinoma (RCC) cells. The anti-tumor effect of lycorine was associated with the induction of ferroptosis. After lycorine treatment, the expression levels of GPX4 in RCC cells decreased, whereas those of ACSL4 increased.
Long-chain-fatty-acid--CoA ligase 4 (ACSL4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Driver
Responsed Disease Hereditary Leiomyomatosis ICD-11: 2C90
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model 786-O cells Renal cell carcinoma Homo sapiens CVCL_1051
A-498 cells Renal cell carcinoma Homo sapiens CVCL_1056
Caki-1 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0234
HK-2 cells Normal Homo sapiens CVCL_0302
Response regulation Lycorine could inhibit the proliferation in human renal cell carcinoma (RCC) cells. The anti-tumor effect of lycorine was associated with the induction of ferroptosis. After lycorine treatment, the expression levels of GPX4 in RCC cells decreased, whereas those of ACSL4 increased.
References
Ref 1 Ferroptosis is involved in the anti-tumor effect of lycorine in renal cell carcinoma cells. Oncol Lett. 2021 Nov;22(5):781. doi: 10.3892/ol.2021.13042. Epub 2021 Sep 13.